Resources
News
Focused Ultrasound Foundation Highlights RebrAIn’s AI Innovations in Neurosurgery
We are excited to share that the Focused Ultrasound Foundation has featured RebrAIn for our pioneering use of artificial intelligence in brain targeting. The article details how our supervised AI-driven platform, Optim MRI, enhances precision and effectiveness in...
L’Usine Digitale Highlights RebrAIn’s €3.7 Million Funding for Supervised AI-Driven Neurosurgery
We are pleased to share that L'Usine Digitale has featured RebrAIn for securing €3.7 million to advance our supervised AI-driven software. This innovative platform is designed to simplify the work of neurosurgeons by enhancing the precision and efficiency of Deep...
La Tribune Features RebrAIn’s €3.7 Million Funding to Aid Neurosurgeons
We are excited to announce that La Tribune has featured RebrAIn for raising €3.7 million.This funding will support the development and commercialization of our supervised AI-driven platform aimed at enhancing Deep Brain Stimulation (DBS) procedures for Parkinson’s...
FrenchWeb Highlights RebrAIn’s €3.7 Million Seed Funding for Parkinson’s Disease Innovation
We are thrilled to share that FrenchWeb has featured RebrAIn for securing €3.7 million in seed funding to advance our AI-driven solutions for treating Parkinson's Disease.Led by Karista and supported by Nouvelle Aquitaine Co-Investissement, this funding will...
Biotech Finances Highlights RebrAIn’s Successful Funding Round for supervised AI Neurosurgery
We are pleased to announce that Biotech Finances has featured RebrAIn in their recent article. RebrAIn has successfully completed a €3.7 million funding round led by Karista, with participation from Nouvelle Aquitaine Co-Investissement and existing investors. Our...
La Tribune Features RebrAIn’s AI Solutions for Parkinson’s Disease Treatment
We are proud to announce that La Tribune has featured RebrAIn in their recent article discussing the role of AI in treating Parkinson's Disease.The article and the video highlights our supervised AI-driven platform, developed by Professor Emmanuel Cuny and Dr. Nejib...
User’s manual
Last release
OptimMRI US
OptimDBS EU
- CUG_OptimDBS-IT-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_4.pdf (Revision #4| Revision date: 2024-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: FR)
Information notice
All revisions of the instructions manual are available for download below, in English and other languages. This manual details how to retreive and use the marked MRIs for surgery planning. Marked MRIs (3D DICOM) contain the targets as predicted by OptimDBS, a standalone tool developed by RebrAIn.
The use of those marked MRIs processed by OptimDBS is restricted to clinicians planning neurosurgery for patients with either Parkinson’s disease or essential tremor, by targeting the subthalamic nucleus (STN) or the ventral intermediate nucleus of the thalamus (VIM).
Carefully reading this instructions manual before use is strongly advised.
Any type of inappropriate use is prohibited.
A hard copy of this instructions manual can be obtained within 5 working days with no extra charge by contacting Rebrain at the following email address: support@rebrain.eu.
RebrAIn provides its partners with an access to its secure medical data exchange platform at transfer.rebrain.eu. Please contact our team with the above email address or via this website’s contact form to request an account. The current version of the instructions manual is also available for download on the data exchange platform, through the help menu of a connected account.
The instructions manuals below are available in PDF format. Any standard PDF reader, such as Acrobat Reader or Okular, is necessary
Sont disponibles dans la liste ci-dessous toutes les versions du manuel d’utilisation électronique en Français et dans d’autres langues. Ce manuel d’utilisation explique comment récupérer et utiliser lors la planification de la chirurgie les IRM marquées avec des cibles cérébrales prédites par OptimDBS, un logiciel autonome conçu par RebrAIn.
L’utilisation de ces images IRM (3D DICOM) marquées traitées avec OptimDBS est réservée au clinicien prévoyant d’effectuer une intervention neurochirurgicale pour le traitement de patient atteints de la maladie de Parkinson ou de Tremblements Essentiels en ciblant le noyau sous-thalamique, STN, ou le noyau ventral intermédiaire, VIM.
Il est recommandé de lire attentivement ce manuel d’instructions avant utilisation.
Toute utilisation inappropriée est interdite.
Une copie imprimée des instructions d’utilisation peut être obtenue dans les 5 jours ouvrés sans frais supplémentaires en contactant RebrAIn à l’adresse email suivante : support@rebrain.eu.
RebrAIn offre à ses collaborateur un accès à son service sécurisé d’échange de données médicales à transfer.rebrain.eu. Vous pouvez contacter l’équipe via le formulaire de contact pour faire la demande d’un compte. La version courante du manuel d’utilisation électronique est également accessible depuis le menu « Aide » sur la plateforme transfer.rebrain.eu une fois connecté à celle-ci.
Ces instructions d’utilisation sont fournies en format « PDF ». Un logiciel approprié, tel que Adobe Acrobat Reader, est requis pour les lire.
Archives
- CUG_OptimDBS-IT-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: FR)
- CUG_OptimDBS EN Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: EN)
- CUG_OptimDBS FR Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: FR)
Publications
White Paper
OptimMRI from RebrAIn
A personalized, participative, preventive, predictive and evidence-based neurosurgical targeting service for patients with movement disorders caused by Parkinson’s Disease or Essential Tremor.
To receive our complete white paper on OptimMRI, please submit your request via the form below. Your details will help us verify eligibility and ensure the information is sent to the right audience.
